Zoltan Dekan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5669962/publications.pdf

Version: 2024-02-01

35 papers	1,409 citations	471509 17 h-index	361022 35 g-index
36 all docs	36 docs citations	36 times ranked	1654 citing authors

#	Article	IF	Citations
1	Multitarget nociceptor sensitization by a promiscuous peptide from the venom of the King Baboon spider. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	7
2	The Tarantula Toxin Ï‰-Avsp1a Specifically Inhibits Human CaV3.1 and CaV3.3 via the Extracellular S3-S4 Loop of the Domain 1 Voltage-Sensor. Biomedicines, 2022, 10, 1066.	3.2	2
3	Olfactory bulbâ€targeted quantum dot (QD) bioconjugate and Kv1.3 blocking peptide improve metabolic health in obese male mice. Journal of Neurochemistry, 2021, 157, 1876-1896.	3.9	15
4	Nature-inspired dimerization as a strategy to modulate neuropeptide pharmacology exemplified with vasopressin and oxytocin. Chemical Science, 2021, 12, 4057-4062.	7.4	12
5	Production, composition, and mode of action of the painful defensive venom produced by a limacodid caterpillar, Doratifera vulnerans. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	17
6	The Tarantula Venom Peptide Eo1a Binds to the Domain II S3-S4 Extracellular Loop of Voltage-Gated Sodium Channel NaV1.8 to Enhance Activation. Frontiers in Pharmacology, 2021, 12, 789570.	3.5	4
7	Fulditoxin, representing a new class of dimeric snake toxins, defines novel pharmacology at nicotinic ACh receptors. British Journal of Pharmacology, 2020, 177, 1822-1840.	5.4	12
8	Mutational analysis of ProTx-I and the novel venom peptide Pe1b provide insight into residues responsible for selective inhibition of the analgesic drug target NaV1.7. Biochemical Pharmacology, 2020, 181, 114080.	4.4	7
9	Addition of K22 Converts Spider Venom Peptide Pme2a from an Activator to an Inhibitor of NaV1.7. Biomedicines, 2020, 8, 37.	3.2	6
10	It Takes Two: Dimerization Is Essential for the Broad-Spectrum Predatory and Defensive Activities of the Venom Peptide Mp1a from the Jack Jumper Ant Myrmecia pilosula. Biomedicines, 2020, 8, 185.	3.2	12
11	Mapping the Molecular Surface of the Analgesic NaV1.7-Selective Peptide Pn3a Reveals Residues Essential for Membrane and Channel Interactions. ACS Pharmacology and Translational Science, 2020, 3, 535-546.	4.9	16
12	A tetrapeptide class of biased analgesics from an Australian fungus targets the Âμ-opioid receptor. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22353-22358.	7.1	31
13	Antiallodynic effects of the selective NaV1.7 inhibitor Pn3a in a mouse model of acute postsurgical pain: evidence for analgesic synergy with opioids and baclofen. Pain, 2019, 160, 1766-1780.	4.2	35
14	Novel venom-derived inhibitors of the human EAG channel, a putative antiepileptic drug target. Biochemical Pharmacology, 2018, 158, 60-72.	4.4	13
15	PHAB toxins: a unique family of predatory sea anemone toxins evolving via intra-gene concerted evolution defines a new peptide fold. Cellular and Molecular Life Sciences, 2018, 75, 4511-4524.	5.4	34
16	Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a. Scientific Reports, 2017, 7, 40883.	3.3	120
17	Î”â€Myrtoxinâ€Mp1a is a Helical Heterodimer from the Venom of the Jack Jumper Ant that has Antimicrobial, Membraneâ€Disrupting, and Nociceptive Activities. Angewandte Chemie - International Edition, 2017, 56, 8495-8499.	13.8	28
18	Î”â€Myrtoxinâ€Mp1a is a Helical Heterodimer from the Venom of the Jack Jumper Ant that has Antimicrobial, Membraneâ€Disrupting, and Nociceptive Activities. Angewandte Chemie, 2017, 129, 8615-8619.	2.0	1

#	Article	IF	Citations
19	Modulatory features of the novel spider toxin Î¼â€TRTXâ€Df1a isolated from the venom of the spider Davus fasciatus. British Journal of Pharmacology, 2017, 174, 2528-2544.	5.4	46
20	Novel Human Eag Channel Antagonists from Spider Venoms. Biophysical Journal, 2017, 112, 332a.	0.5	0
21	Conotoxin Î¦â€MiXXVIIA from the Superfamily G2 Employs a Novel Cysteine Framework that Mimics Granulin and Displays Antiâ€Apoptotic Activity. Angewandte Chemie, 2017, 129, 15169-15172.	2.0	3
22	Conotoxin Î¦â€MiXXVIIA from the Superfamily G2 Employs a Novel Cysteine Framework that Mimics Granulin and Displays Antiâ€Apoptotic Activity. Angewandte Chemie - International Edition, 2017, 56, 14973-14976.	13.8	25
23	Analgesic Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of NaV1.7-Mediated Pain. Toxins, 2016, 8, 78.	3.4	94
24	Selective spider toxins reveal a role for the Nav1.1 channel in mechanical pain. Nature, 2016, 534, 494-499.	27.8	239
25	Development of a Î¼O-Conotoxin Analogue with Improved Lipid Membrane Interactions and Potency for the Analgesic Sodium Channel NaV1.8. Journal of Biological Chemistry, 2016, 291, 11829-11842.	3.4	37
26	Xenopus borealis as an alternative source of oocytes for biophysical and pharmacological studies of neuronal ion channels. Scientific Reports, 2015, 5, 14763.	3.3	12
27	Identification and Characterization of ProTx-III [Î¼-TRTX-Tp1a], a New Voltage-Gated Sodium Channel Inhibitor from Venom of the Tarantula Thrixopelma pruriens. Molecular Pharmacology, 2015, 88, 291-303.	2.3	72
28	Selenoether oxytocin analogues have analgesic properties in a mouse model of chronic abdominal pain. Nature Communications, 2014, 5, 3165.	12.8	122
29	Total Synthesis of Human Hepcidin through Regioselective Disulfideâ€Bond Formation by using the Safetyâ€Catch Cysteine Protecting Group 4,4â€²â€Dimethylsulfinylbenzhydryl. Angewandte Chemie - International Edition, 2014, 53, 2931-2934.	13.8	46
30	A Tarantula-Venom Peptide Antagonizes the TRPA1 Nociceptor Ion Channel by Binding to the S1â€“S4 Gating Domain. Current Biology, 2014, 24, 473-483.	3.9	56
31	Conotoxin engineering: dual pharmacophoric noradrenaline transport inhibitor/integrin binding peptide with improved stability. Organic and Biomolecular Chemistry, 2012, 10, 5791.	2.8	13
32	Isolation, characterization and total regioselective synthesis of the novel Î¼O-conotoxin MfVIA from Conus magnificus that targets voltage-gated sodium channels. Biochemical Pharmacology, 2012, 84, 540-548.	4.4	54
33	Î±-Conotoxin ImI Incorporating Stable Cystathionine Bridges Maintains Full Potency and Identical Three-Dimensional Structure. Journal of the American Chemical Society, 2011, 133, 15866-15869.	13.7	81
34	Modulating Oxytocin Activity and Plasma Stability by Disulfide Bond Engineering. Journal of Medicinal Chemistry, 2010, 53, 8585-8596.	6.4	112
35	Synthesis and InÂvitro Biological Activity of Cyclic Lipophilic Ï‡-Conotoxin MrIA Analogues. International Journal of Peptide Research and Therapeutics, 2007, 13, 307-312.	1.9	8